State law can’t compel ‘patent dance’, rules Federal Circuit
15-12-2017
BIO 2017: Panellists talk Amgen Sandoz biosimilar battle
23-06-2017
Fed Circuit erred in Sandoz v Amgen, says solicitor general
28-02-2017
sprng23 / iStockphoto.com
The US Supreme Court has ruled that biosimilar applicants may provide notice to the manufacturer before obtaining a licence from the Food and Drug Administration (FDA) for their biosimilars.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
SCOTUS, Amgen, Sandoz, Neupogen, biologics, biosimilar, FDA, BPCIA, US Supreme Court
